12:00 AM
Apr 07, 2016
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MAP kinase kinase kinase kinase 3 (MAP4K3; GLK); kruppel-like factor 2 (KLF2); kruppel-like factor 4 (KLF4; EZF)

Cardiovascular disease

INDICATION: Cardiovascular

Patient sample and mouse studies suggest inhibiting the MAP4K3-KLF2/KLF4 pathway could help treat cerebral cavernous malformations (CCMs), which involve the formation of highly dilated blood vessels and symptoms including headaches, seizures and hemorrhages. In cerebral vascular cells...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >